List of Excipients in Branded Drug UROXATRAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	UROXATRAL	alfuzosin hydrochloride	54868-5046	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	UROXATRAL	alfuzosin hydrochloride	54868-5046	ETHYLCELLULOSE
Physicians Total Care Inc	UROXATRAL	alfuzosin hydrochloride	54868-5046	FERRIC OXIDE YELLOW
Physicians Total Care Inc	UROXATRAL	alfuzosin hydrochloride	54868-5046	HYDROGENATED CASTOR OIL
Physicians Total Care Inc	UROXATRAL	alfuzosin hydrochloride	54868-5046	HYPROMELLOSES
Physicians Total Care Inc	UROXATRAL	alfuzosin hydrochloride	54868-5046	MAGNESIUM STEARATE

Uroxatral Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 6, 2026

Uroxatral is the branded extended-release formulation of alfuzosin hydrochloride, approved for the treatment of the signs and symptoms of benign prostatic hyperplasia. Its commercial value is tied to controlled drug release, food-dependent exposure, dose uniformity, and low-cost generic manufacturability. The formulation is mature, generic alfuzosin extended-release competition is established, and the strongest commercial opportunities are in excipient substitution, controlled-release technology, contract manufacturing, and differentiated dosage forms rather than new-chemical-entity exclusivity.

What excipients protect the Uroxatral formulation?

Uroxatral 10 mg extended-release tablets use a conventional hydrophilic and hydrophobic matrix system. The U.S. label identifies the following inactive ingredients:

Excipient	Probable formulation role
Microcrystalline cellulose	Tablet filler, compression aid, structural matrix component
Hypromellose	Hydrophilic release-controlling polymer and binder
Ethylcellulose	Water-insoluble release modifier
Hydrogenated castor oil	Hydrophobic matrix former and lubricant
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Yellow ferric oxide	Colorant

The combination of hypromellose, ethylcellulose, and hydrogenated castor oil controls water penetration, gel formation, tablet erosion, and alfuzosin diffusion. Uroxatral must be swallowed whole. Crushing or chewing can alter the release profile and may increase exposure to the extended-release dose [1].

The formulation does not appear to depend on a complex delivery device, osmotic pump, gastroretentive system, or multiparticulate capsule. That structure lowers manufacturing complexity but also reduces the number of formulation barriers available to defend the product commercially.

How does the Uroxatral excipient system control drug release?

Alfuzosin hydrochloride is incorporated into a matrix tablet rather than delivered as an immediate-release tablet. Hypromellose hydrates after gastrointestinal contact and forms a gel layer. Ethylcellulose and hydrogenated castor oil reduce water ingress and drug diffusion. The result is a prolonged release profile intended to support once-daily dosing.

The principal critical quality attributes are:

• Extended-release dissolution across multiple pH conditions
• Dose uniformity at the 10 mg strength
• Tablet hardness and friability
• Resistance to dose dumping after mechanical damage
• Stability under heat and humidity
• Consistent release after food administration
• Physical compatibility between alfuzosin and polymeric excipients

The label instructs patients to take Uroxatral once daily immediately after the same meal each day. Food increases alfuzosin exposure and changes absorption compared with fasting administration [1]. That requirement creates a formulation-development constraint. A generic or reformulated product must demonstrate comparable exposure under the relevant fed condition and maintain acceptable dissolution performance.

Key excipient risks

Hypromellose grade is a major source of performance variation. Differences in viscosity, particle size, substitution pattern, and hydration behavior can materially change dissolution. Ethylcellulose also varies by viscosity grade, particle characteristics, and coating or dispersion behavior.

Hydrogenated castor oil can affect granule lubrication, tablet compression, and hydrophobicity. Excessive magnesium stearate or over-lubrication can slow wetting and alter release. Povidone grade and concentration can change granule strength and drug distribution.

These variables create opportunities for excipient suppliers that can provide:

• Narrow-viscosity hypromellose grades
• Co-processed matrix excipients
• Low-peroxide and low-moisture polymers
• Direct-compression grades
• Continuous-manufacturing-compatible excipients
• Excipient systems with demonstrated dissolution similarity to reference alfuzosin ER

What patents protect Uroxatral and alfuzosin extended release?

Uroxatral is a small-molecule product and does not have biosimilar exclusivity. Its original pharmaceutical and formulation patent estate has matured, and generic alfuzosin extended-release tablets are commercially available in the United States.

The relevant protection categories historically included:

1. Alfuzosin composition-of-matter protection.
2. Extended-release tablet and controlled-release formulation claims.
3. Treatment claims for benign prostatic hyperplasia.
4. Manufacturing and dosage-form claims.
5. Regulatory exclusivity associated with the original NDA.

The current commercial position is materially different from the launch period. FDA-approved generic alfuzosin ER products compete directly with Uroxatral, and the principal barriers are regulatory equivalence, manufacturing economics, and supply reliability rather than active composition-of-matter exclusivity [2].

The FDA Orange Book is the controlling source for current listed patents, exclusivity, therapeutic equivalence, and reference-listed-drug status. Historical patent rights should not be treated as active without confirmation against the current Orange Book entry for NDA 021287 [2].

When did Uroxatral lose exclusivity and when do generic products enter?

Uroxatral was approved by the FDA in 2003. The product’s market exclusivity has expired, and generic alfuzosin hydrochloride extended-release tablets are available.

Milestone	Commercial significance
2003 FDA approval	Established Uroxatral as the U.S. reference product
Post-approval patent period	Limited early generic entry
Generic approval period	Opened direct substitution and price competition
Current market	Mature multisource generic market

Unlike a product with a live pediatric or orphan exclusivity period, Uroxatral does not have a current regulatory exclusivity structure that materially prevents generic competition. The commercial issue is therefore substitution share, reimbursement tier placement, and manufacturing cost.

What is the Orange Book status of Uroxatral?

Uroxatral is associated with NDA 021287 and the active ingredient alfuzosin hydrochloride. The Orange Book identifies the reference product and therapeutic-equivalence framework for approved generic versions [2].

The Orange Book is most relevant to four questions:

• Whether a patent is currently listed against the reference product
• Whether an applicant must certify under Paragraph IV
• Whether a generic has an AB therapeutic-equivalence rating
• Whether the reference product remains commercially available

For a mature product such as Uroxatral, an applicant’s risk is usually driven by product-specific bioequivalence and dissolution requirements rather than a complex patent challenge. Paragraph IV litigation was more relevant during the initial generic-entry period. Current entrants generally face lower patent risk but must still address any active Orange Book-listed claims and regulatory deficiencies.

Which companies are challenging or competing with Uroxatral?

The competitive field includes generic manufacturers of alfuzosin ER and branded or generic alpha-1 blockers used for BPH.

Product	Active ingredient	Dosage form	Competitive relationship
Uroxatral	Alfuzosin hydrochloride	Extended-release tablet	Reference product
Generic alfuzosin ER	Alfuzosin hydrochloride	Extended-release tablet	Direct substitution
Flomax and generic tamsulosin	Tamsulosin hydrochloride	Modified-release capsule/tablet	Therapeutic competitor
Rapaflo and generic silodosin	Silodosin	Capsule	Therapeutic competitor
Hytrin and generic terazosin	Terazosin	Immediate-release tablet	Therapeutic competitor
Cardura and generic doxazosin	Doxazosin	Immediate- or extended-release tablet	Therapeutic competitor

The strongest direct competition comes from generic alfuzosin ER. Tamsulosin is the larger therapeutic benchmark in many BPH formularies because of broad physician familiarity, extensive generic availability, and established once-daily dosing.

What formulation patents and manufacturing barriers remain?

The principal barrier is regulatory equivalence, not a broad patent moat. A generic applicant must reproduce the performance of a modified-release oral dosage form through in vitro dissolution and, where required, pharmacokinetic studies.

Key technical risks include:

• Failure to match fed-state exposure
• Dissolution divergence in high-pH or low-pH media
• Alcohol-induced dose dumping
• Tablet failure during shipping or handling
• Polymer batch variability
• Inadequate control of tablet porosity
• Changes in release after scale-up
• Stability failure caused by moisture ingress
• Inconsistent release after switching excipient suppliers

Manufacturers can reduce these risks through design-of-experiments work on polymer viscosity, hydrophobic excipient loading, granulation endpoint, compression force, and lubricant concentration.

A formulation that uses a different polymer architecture may obtain a differentiated regulatory position, but it would not automatically create meaningful patent value. The product must show clinical or commercial benefit, such as lower food sensitivity, better swallowing characteristics, smaller tablet size, improved dose robustness, or reduced manufacturing cost.

What excipient opportunities exist for Uroxatral generics?

1. Polymer substitution

A generic manufacturer can evaluate alternative hypromellose and ethylcellulose grades, including co-processed systems. The opportunity is to reduce supplier concentration and improve release reproducibility without changing the product’s therapeutic performance.

The highest-value suppliers will provide comparative dissolution data, scale-up support, and documentation for pharmaceutical-quality systems.

2. Direct compression

A direct-compression platform could reduce granulation time, solvent use, and process complexity. The main challenge is maintaining uniform alfuzosin distribution and consistent matrix structure at relatively low drug loading.

3. Co-processed excipients

Co-processed microcrystalline cellulose, polymer, and flow-aid systems may improve tabletability and reduce the number of raw materials. This can lower manufacturing complexity, but the formulation must be requalified for dissolution and stability.

4. Smaller or easier-to-swallow tablets

Uroxatral is an oral tablet used primarily by older men, a population with a meaningful risk of dysphagia and polypharmacy. A smaller tablet or alternative extended-release dosage form could support product differentiation. Any new dosage form would require a separate regulatory strategy and may not qualify as a simple generic equivalent.

5. Low-cost supply agreements

The most practical commercial opportunity is often supply rather than novel formulation IP. Long-term agreements for hypromellose, ethylcellulose, hydrogenated castor oil, and direct-compression excipients can improve gross margin and reduce shortage exposure.

How strong is the Uroxatral patent estate?

The current patent estate is weak as a barrier to generic entry because the core product is mature and generic versions are approved. The remaining defensibility is more likely to come from:

• Know-how regarding dissolution matching
• Scale-up process controls
• Supplier qualification
• Manufacturing cost
• Regulatory filing execution
• Customer contracts
• Reliable API and excipient supply

An excipient supplier could pursue composition or process patents for a new controlled-release matrix, but the patent would need to be materially distinct from expired alfuzosin and conventional extended-release matrix technology. Broad claims covering hypromellose, ethylcellulose, or hydrogenated castor oil alone would face substantial prior-art risk.

What generic launch risks exist for alfuzosin extended release?

Generic launch risk is moderate for a technically competent manufacturer and low from a basic patent perspective.

Risk	Assessment	Commercial effect
Active composition patent	Low	Limited barrier
Formulation patent	Low to moderate	Depends on current Orange Book records
Bioequivalence	Moderate	Fed-state and ER performance are critical
Excipient supply	Moderate	Polymer variability can delay approval
Price erosion	High	Mature generic market
Therapeutic substitution	High	Tamsulosin and silodosin compete
Manufacturing complexity	Moderate	Matrix release is manageable but sensitive
Biosimilar competition	None	Alfuzosin is a small molecule

A new entrant is likely to compete on manufacturing cost, wholesaler access, supply reliability, and formulary status. A premium-priced generic without a clear dosage-form advantage has limited commercial leverage.

What licensing deals affect the Uroxatral excipient market?

No major publicly disclosed active licensing structure is central to the current Uroxatral excipient market. The opportunity is more likely to involve bilateral arrangements among:

• Generic drug manufacturers
• Controlled-release excipient suppliers
• Contract development and manufacturing organizations
• API suppliers
• Specialty pharmaceutical distributors

Potential deal structures include formulation-development services, preferred-supplier agreements, excipient technology licenses, and technology-transfer packages. The most defensible package would combine a validated polymer system with manufacturing instructions, dissolution specifications, stability data, and regulatory-support documentation.

How does Uroxatral compare with tamsulosin from an excipient perspective?

Uroxatral and tamsulosin compete therapeutically but differ in dosage-form economics.

Attribute	Uroxatral	Tamsulosin
Active ingredient	Alfuzosin	Tamsulosin
Common release platform	Extended-release tablet	Modified-release capsule or tablet
Food instruction	Immediate post-meal dosing is important	Product-specific food instructions
Excipient opportunity	Matrix-polymer optimization	Multiparticulate or capsule-system optimization
Generic maturity	Mature	Highly mature
Commercial differentiation	Limited	Limited but broader market scale
Main barrier	Fed-state release matching	Modified-release performance and capsule or pellet manufacture

Uroxatral may offer more opportunity for tablet-matrix optimization, while tamsulosin may offer more opportunity in pellet coating, capsule filling, and alternative modified-release systems.

What revenue exposure and commercial opportunities exist?

Sanofi does not generally disclose Uroxatral revenue as a standalone current growth asset. The product should be treated as a mature, declining or stable branded franchise rather than a high-growth specialty product.

Commercial opportunities are concentrated in four areas:

1. Low-cost generic manufacturing.
2. Excipient supply and dual-sourcing.
3. Contract development of controlled-release alfuzosin products.
4. Reformulated BPH products with improved swallowing, food flexibility, or adherence.

The strongest near-term opportunity is a cost-optimized generic supported by a robust excipient-control strategy. The weakest opportunity is a premium formulation with no demonstrated clinical or adherence benefit.

Key Takeaways

• Uroxatral is alfuzosin hydrochloride 10 mg in an extended-release tablet.
• Its principal excipients are hypromellose, ethylcellulose, hydrogenated castor oil, microcrystalline cellulose, povidone, magnesium stearate, colloidal silicon dioxide, and yellow ferric oxide.
• Release performance depends on the interaction of hydrophilic and hydrophobic matrix excipients.
• Generic alfuzosin ER competition is established, and biosimilar risk does not apply.
• The current patent barrier is substantially weaker than the technical and commercial barriers.
• Fed-state pharmacokinetics, dissolution matching, polymer variability, and scale-up are the principal development risks.
• Excipient suppliers can create value through polymer substitution, co-processed systems, direct compression, dual sourcing, and regulatory support.
• A differentiated product would need a measurable advantage in food flexibility, swallowing, adherence, stability, or cost.

FAQs About Uroxatral Excipients and Commercial Strategy

Can Uroxatral excipients be replaced in a generic product?

Yes. Generic manufacturers can use different inactive ingredients if the product meets FDA requirements for quality, bioequivalence, stability, safety, and extended-release performance.

Does Uroxatral contain lactose or gluten-derived excipients?

The U.S. label lists microcrystalline cellulose, hypromellose, ethylcellulose, hydrogenated castor oil, povidone, magnesium stearate, colloidal silicon dioxide, and yellow ferric oxide. Lactose and wheat-derived excipients are not listed [1].

Is alfuzosin ER subject to biosimilar competition?

No. Alfuzosin is a chemically synthesized small molecule. Competition occurs through abbreviated new drug applications and generic substitution, not the biosimilar pathway.

Can a new alfuzosin formulation obtain patent protection?

Potentially, but protection would need to rely on a novel and non-obvious formulation, manufacturing process, dosage form, or clinical-use feature. Conventional use of established matrix excipients would face significant prior-art challenges.

What is the best excipient opportunity for a Uroxatral generic?

A controlled-release polymer platform that improves dissolution reproducibility, reduces manufacturing cost, and supports dual sourcing is the most practical opportunity. The commercial value increases if the platform also simplifies scale-up and regulatory documentation.

References

1. U.S. Food and Drug Administration. (2023). Uroxatral (alfuzosin hydrochloride) extended-release tablets, 10 mg: Prescribing information. Sanofi-Aventis U.S. LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/

4. United States Pharmacopeia. (2024). General chapter <711>: Dissolution. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry.